- Home
- TCRX vs POWW Comparison
TCRX vs POWW Comparison
Compare TCRX & POWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- POWW
- Stock Information
- Founded
- TCRX 2018
- POWW 1990
- Country
- TCRX United States
- POWW United States
- Employees
- TCRX N/A
- POWW N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- POWW Ordnance And Accessories
- Sector
- TCRX Health Care
- POWW Industrials
- Exchange
- TCRX Nasdaq
- POWW Nasdaq
- Market Cap
- TCRX 170.1M
- POWW 144.9M
- IPO Year
- TCRX 2021
- POWW N/A
- Fundamental
- Price
- TCRX $2.40
- POWW $1.50
- Analyst Decision
- TCRX Strong Buy
- POWW Hold
- Analyst Count
- TCRX 5
- POWW 1
- Target Price
- TCRX $11.40
- POWW $1.50
- AVG Volume (30 Days)
- TCRX 544.4K
- POWW 1.1M
- Earning Date
- TCRX 03-05-2025
- POWW 02-06-2025
- Dividend Yield
- TCRX N/A
- POWW N/A
- EPS Growth
- TCRX N/A
- POWW N/A
- EPS
- TCRX N/A
- POWW N/A
- Revenue
- TCRX $9,362,000.00
- POWW $135,498,023.00
- Revenue This Year
- TCRX N/A
- POWW $5.67
- Revenue Next Year
- TCRX $5.14
- POWW $4.86
- P/E Ratio
- TCRX N/A
- POWW N/A
- Revenue Growth
- TCRX N/A
- POWW N/A
- 52 Week Low
- TCRX $2.38
- POWW $0.95
- 52 Week High
- TCRX $9.69
- POWW $2.94
- Technical
- Relative Strength Index (RSI)
- TCRX 25.27
- POWW 72.98
- Support Level
- TCRX $2.60
- POWW $1.30
- Resistance Level
- TCRX $2.85
- POWW $1.40
- Average True Range (ATR)
- TCRX 0.17
- POWW 0.10
- MACD
- TCRX 0.00
- POWW 0.03
- Stochastic Oscillator
- TCRX 2.41
- POWW 97.87
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About POWW AMMO Inc.
AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.